Skip to main content
Atrás
Watch Compare

Pyxis Oncology, Inc.

Calidad de datos: 100%
PYXS
Nasdaq Manufacturing Chemicals
$1.59
▲ $0.12 (8.16%)
Cap. Mercado: 99.90 M
Precio
$1.59
Cap. Mercado
99.90 M
Rango del Día
$1.43 — $1.59
Rango de 52 Semanas
$0.87 — $5.55
Volumen
609,602
Apertura $1.46
Promedio 50D / 200D
$1.47
8.18% above
Promedio 50D / 200D
$2.12
24.95% below

Quick Summary

Puntos Clave

Negative free cash flow of -63.51 M
Capital efficient — spends only 0.06% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)-14.17%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-101.80%
Below sector avg (-51.02%)
ROIC-69.56%
Net Margin-574.55%
Op. Margin-609.18%

Seguridad

Debt / Equity
N/A
Current Ratio4.29
Interest CoverageN/A

Valoración

PE (TTM)
-1.25
Above sector avg (-1.98)
P/B Ratio1.45
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (44 pares)
Métrica Acción Mediana del Sector
P/E -1.3 -2.0
P/B 1.5 5.1
ROE % -101.8 -51.0
Net Margin % -574.6 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -14.17% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 13.86 M Net Income (TTM) -79.62 M
ROE -101.80% ROA -69.59%
Gross Margin N/A Operating Margin -609.18%
Net Margin -574.55% Free Cash Flow (TTM) -63.51 M
ROIC -69.56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.29
Interest Coverage N/A Asset Turnover 0.12
Working Capital 63.69 M Tangible Book Value 66.35 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.25 Forward P/E N/A
P/B Ratio 1.45 P/S Ratio 7.21
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -63.57%
Market Cap 99.90 M Enterprise Value 90.98 M
Per Share
EPS (Diluted TTM) -1.28 Revenue / Share 0.22
FCF / Share -1.01 OCF / Share -1.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.06% FCF Conversion 79.77%
SBC-Adj. FCF -76.21 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 13.86 M 16.15 M — — —
Net Income -79.62 M -77.33 M -73.79 M -120.72 M -75.98 M
EPS (Diluted) -1.28 -1.32 -1.85 -3.65 —
Gross Profit — — — — —
Operating Income -84.42 M -89.46 M -82.20 M -123.48 M -69.72 M
EBITDA — — — — —
R&D Expenses 73.70 M 58.75 M 49.59 M 86.13 M 51.05 M
SG&A Expenses — — — — —
D&A 4.51 M 2.98 M 1.93 M 709,000.0 647,000.0
Interest Expense — — — — —
Income Tax 1.39 M -2.16 M — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 91.52 M 157.18 M 173.73 M 211.38 M 280.02 M
Total Liabilities 38.11 M 36.43 M 48.02 M 50.56 M 18.71 M
Shareholders' Equity 53.41 M 120.75 M 125.70 M 160.82 M 261.31 M
Total Debt — — — — —
Cash & Equivalents 15.42 M 19.47 M 9.66 M 179.29 M 274.74 M
Current Assets 72.11 M 132.44 M 124.60 M 186.61 M 278.67 M
Current Liabilities 21.13 M 17.68 M 25.76 M 31.63 M 18.71 M